|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustment to reconcile net loss to net cash: | |||||
| Depreciation and amortization | |||||
| Provision for bad debt | |||||
| Impairment of assets | |||||
| Impairment of non-marketable securities | |||||
| Common stock-based compensation and expenses, net | |||||
| Profit/Loss on sale of fixed assets, net | |||||
| Forgiveness of PPP Loan | |||||
| Changes in: | |||||
| Accounts receivables, net | |||||
| Inventory | |||||
| Deposits and advances | |||||
| Claims and advances | |||||
| Accounts payable | |||||
| Accrued and other liabilities | |||||
| Operating lease asset | |||||
| Operating lease liability | |||||
| Net cash used in operating activities | |||||
| Cash flow from investing activities: | |||||
| Purchase of property, plant, and equipment | |||||
| Sale of property, plant, and equipment | |||||
| Investment in short-term investments | |||||
| Proceeds from short-term investments | |||||
| Acquisition and development of intangible assets | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Net proceeds from the issuance of common stock | |||||
| Proceeds from common stock subscribed | |||||
| Repayment of long-term loan | |||||
| Net cash provided by financing activities | |||||
| Effects of exchange rate changes on cash and cash equivalents | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents at the beginning of the period | |||||
| Cash and cash equivalents at the end of the period | |||||
| Non-cash items: | |||||
| Common stock issued/granted for stock-based compensation, including patent acquisition | |||||
| Forgiveness of PPP Loan | |||||
Loading...
